Ocular Therapeutix (OCUL) Retained Earnings (2013 - 2026)

Ocular Therapeutix has reported Retained Earnings for 14 years, with the latest figure at -$1.3 billion in Q2 2026.

• Retained Earnings for Q2 2026 came in at -$1.3 billion, down 29.47% year-over-year; the trailing twelve-month figure through Jun 2026 was -$1.3 billion (down 29.47% YoY), and the FY2025 annual result was -$1.2 billion, down 29.84% from the prior year.
• Retained Earnings declined to -$1.3 billion in Q2 2026, from -$1.2 billion in the prior quarter.
• Over five years, Retained Earnings peaked at -$558.3 million in Q1 2022 and troughed at -$1.3 billion in Q2 2026.
• A 5-year average of -$840.8 million and a median of -$784.3 million in 2024 frame the typical range for Retained Earnings.
• The widest annual swing landed in 2022, when Retained Earnings decreased 4.14%; it then sank 30.41% in 2026.
• A 5-year view of Retained Earnings shows it stood at -$616.8 million in 2022, then fell by 13.09% to -$697.6 million in 2023, then fell by 27.74% to -$891.1 million in 2024, then retreated by 29.84% to -$1.2 billion in 2025, then decreased by 14.47% to -$1.3 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$1.3 billion in Q2 2026, -$1.2 billion in Q1 2026, and -$1.2 billion in Q4 2025.